Nisa Investment Advisors LLC Buys 18,490 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Nisa Investment Advisors LLC increased its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 3,361.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 19,040 shares of the biopharmaceutical company’s stock after acquiring an additional 18,490 shares during the period. Nisa Investment Advisors LLC’s holdings in Sage Therapeutics were worth $413,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of SAGE. Advisor Group Holdings Inc. raised its position in Sage Therapeutics by 63.6% in the 1st quarter. Advisor Group Holdings Inc. now owns 11,406 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 4,432 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Sage Therapeutics by 3.0% during the 1st quarter. Bank of New York Mellon Corp now owns 352,623 shares of the biopharmaceutical company’s stock worth $11,672,000 after acquiring an additional 10,134 shares during the period. MetLife Investment Management LLC acquired a new stake in Sage Therapeutics during the 1st quarter worth $34,000. Vanguard Group Inc. grew its holdings in Sage Therapeutics by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 4,625,003 shares of the biopharmaceutical company’s stock worth $153,088,000 after acquiring an additional 46,762 shares during the period. Finally, First Trust Advisors LP grew its holdings in Sage Therapeutics by 4.1% during the 1st quarter. First Trust Advisors LP now owns 844,652 shares of the biopharmaceutical company’s stock worth $27,958,000 after acquiring an additional 33,218 shares during the period. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Trading Down 19.6 %

Shares of NASDAQ SAGE opened at $12.57 on Thursday. The firm has a market cap of $755.58 million, a PE ratio of -1.39 and a beta of 0.86. Sage Therapeutics, Inc. has a 1-year low of $10.92 and a 1-year high of $59.99. The company has a fifty day moving average price of $20.06 and a 200 day moving average price of $20.96.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm had revenue of $77.97 million during the quarter, compared to analyst estimates of $60.15 million. During the same period in the prior year, the business earned ($2.47) EPS. The company’s revenue for the quarter was up 2621.5% compared to the same quarter last year. Equities research analysts forecast that Sage Therapeutics, Inc. will post -6.06 EPS for the current year.

Wall Street Analyst Weigh In

SAGE has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $28.00 target price on shares of Sage Therapeutics in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday, March 26th. Bank of America lowered shares of Sage Therapeutics from a “neutral” rating to an “underperform” rating and lowered their target price for the stock from $24.00 to $14.00 in a report on Wednesday. Morgan Stanley lifted their target price on shares of Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Finally, Royal Bank of Canada lifted their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $40.56.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.